The IBD SmartSelect Composite Rating for iRhythm Technologies rose from 91 to 96 Monday.
Looking For Winning Stocks? How To Invest In Both Bull And Bear Markets
The revised score means the stock currently tops 96% of all other stocks in terms of key performance metrics and technical strength. History shows the top market performers tend to have a 95 or higher score as they launch their major climbs.
iRhythm Technologies is trading within a buy range from a 128.52 entry from a cup without handle.
One weak spot is the company's 55 EPS Rating, which tracks quarterly and annual earnings-per-share growth. Look for that to improve to 80 or better to show it's in the top 20% of all stocks.
Its Accumulation/Distribution Rating of A shows heavy buying by institutional investors over the last 13 weeks.
In Q1, the company reported 0% earnings-per-share growth. Top line growth fell to 20%, down from 24% in the previous quarter.
iRhythm Technologies earns the No. 3 rank among its peers in the Medical-Services industry group. Hims & Hers Health is the No. 1-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
